on behalf of the CHANCE Investigators* Background--We aimed to determine the risk conferred by metabolic syndrome (METS) and diabetes mellitus (DM) to recurrent stroke in patients with minor ischemic stroke or transient ischemic attack from the CHANCE (Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events) trial.
T he metabolic syndrome (METS) refers to a cluster of highly interrelated metabolic risk factors. 1 Regardless of the details of several criteria by different organizations for its diagnosis, 2, 3 it is generally accepted that the prevalence of METS in diverse racial populations is increasing (between 10% and 84%). 4, 5 Previous prospective studies showed that the presence of METS identifies persons at an elevated risk for ischemic stroke or transient ischemic attack (TIA). 6, 7 There are limited data, however, on the relationship between METS and the risk of stroke recurrence. Previous studies found that METS may not be predictive for stroke recurrence in patients with general ischemic stroke, 8, 9 whereas another study demonstrated that METS was associated with higher risk of stroke recurrence in patients with ischemic stroke. 10 The relationship between METS and recurrence of stroke after a stroke or TIA remains controversial. METS was defined for use in persons without diabetes mellitus (DM), but the definition has developed in recent decades to include those with DM. 11, 12 Given a synergistic relationship among these components, the collective entity of METS provides better stroke risk estimates. Nevertheless, this integration of each component of METS made it difficult to understand the effect of DM or other components on stroke recurrence compared with the role of METS as an independent risk factor. Minor ischemic stroke and TIA account for %65% of all acute ischemic cerebrovascular events 13 and lead to a risk of 10% to 15% stroke occurrence within 90 days. 14, 15 Factors associated with a high risk of recurrence in patients with TIA or minor stroke were different from those of general stroke 16 ; however, data from previous studies were derived from trials or cohorts in which patients were recruited weeks or months after their initial event and underestimated early recurrence, especially for minor stroke or TIA. 8, 9, 17 Consequently, the risks of recurrent stroke caused by METS and DM in patients with a minor stroke or TIA should be further examined.
We compared the risk of recurrent stroke in patients with different METS and DM status and minor stroke or TIA from the CHANCE (Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events) trial. Our hypothesis was that METS and DM were associated with an increased risk of recurrent stroke after a minor stroke or TIA.
Methods

Study Patients
The CHANCE trial was a randomized, double-blind, controlled trial that enrolled 5170 patients within 24 hours after onset of minor stroke (National Institutes of Health Stroke Scale [NIHSS] ≤3) or high-risk TIA (ABCD 2 ≥4) from 114 clinical centers in China. [18] [19] [20] In total, 73 (64%) of 114 participating hospitals voluntarily participated in the serum biomarker substudy in the CHANCE trial. The triglyceride and highdensity lipoprotein levels, which are the significant items for the diagnosis of METS, were analyzed in the laboratory using collected serum. A total of 3044 patients in these 73 centers with available triglyceride and high-density lipoprotein levels were included in this analysis.
Standard Protocol Approvals, Registrations, and Patient Consents
The CHANCE trial is registered at ClinicalTrials.gov (identifier NCT00979589). The protocol and data collection of the CHANCE trial were approved by the ethics committee of Beijing Tiantan Hospital and all other study centers. All participants or his or her representatives provided written informed consent before being entered into the study.
Measurements
Baseline demographics and clinical characteristics, including age, sex, medical history of ischemic stroke, TIA, myocardial infarction, angina, congestive heart failure, known atrial fibrillation or flutter, valvular heart disease, hypertension, DM, hypercholesterolemia, and baseline NIHSS and ABCD 2 scores were collected through face-to-face interviews by neurologists from clinical centers. Body mass index (BMI) was calculated as the weight in kilograms divided by the height in meters squared (kg/m 2 ). Blood pressure was measured in the left arm of supine patients using a mercury or electronic sphygmomanometer. Venous blood was drawn from fasting patients 24AE12 hours after randomization in 3044 patients of these 73 centers. 21 Plasma glucose after overnight fasting was then analyzed. The serum specimens were collected and shipped on ice by overnight courier from each participating hospital to Beijing Tiantan Hospital (China), where all data analyses were performed. The triglyceride and high-density lipoprotein levels were analyzed in the laboratory using collected serum by testing personnel blinded to clinical data in Beijing Tiantan Hospital. Data were analyzed with a Roche Modular P800 system. DM was defined as a fasting glucose level ≥7.0 mmol/L (126 mg/dL), self-reported history of DM, or receiving treatment for DM. METS was defined using the definitions of the Chinese Diabetes Society (CDS), 3 which is the only official recommendation for the diagnosis of METS in the Chinese population, and International Diabetes Foundation (IDF). 2 We excluded patients with DM or fasting plasma 
Efficacy Outcomes
The primary efficacy outcome was a new stroke (ischemic or hemorrhagic) within 90 days. 18 Recurrent stroke was defined by the presence of a sudden new symptomatic neurological deficit on a background of stability or improvement after the presenting event. 22 Secondary efficacy outcome contained composite events (ischemic stroke, hemorrhagic stroke, myocardial infarction, or vascular death). 18 All events were evaluated and confirmed by a central adjudication committee that was blinded to the study group assignments. The interaction effect of METS and DM status with antiplatelet therapy group assignment was examined using METS/DM status by treatment group assignment in multivariable Cox models. We further assessed the relationship between METS and DM status and outcomes of minor stroke or TIA using multivariable Cox regression models with the neither group as reference. Adjusted hazards ratios (HRs) and their 95% CIs were calculated. All potential confounding variables were adjusted. The proportional hazards assumption for the Cox models was examined by adding a time-dependent covariate with interaction of METS/DM status and a logarithmic function of survival time in the model. In sensitivity analyses, the relationship between METS/DM status and patient outcomes was assessed by propensity score methods. The generalized propensity score for each METS/DM category was estimated using a nonparsimonious multivariable multinomial logistic regression model. All baseline variables were included to calculate the generalized propensity score. Then, HRs with their CIs were estimated by Cox regression models with adjustment of propensity score or weighting of inverse probability of METS/DM category. 23 We also performed a similar analysis using METS (IDF) criteria in a sensitivity analysis. A 2-sided P<0.05 was considered to be statistically significant. All analyses were performed with SAS software version 9.4 (SAS Institute Inc).
Statistical Analysis
Results
Baseline Characteristics
Among 5170 patients, a total of 3044 patients (59%) with minor stroke or TIA were included from these 73 centers, and 2126 patients (41%) were excluded because of missing data of triglyceride and high-density lipoprotein levels. The patients included in and excluded from the study were well balanced, except for a slightly higher proportion of DM and TIA and less severity in symptom presentation in excluded patients (Table 1) . For the included patients, the baseline characteristics in the clopidogrel-aspirin and aspirin-alone groups were well balanced ( Table 2 ).
The baseline characteristics of 3044 included patients are listed in Table 3 . Of the 3044 participants, the average age was 62.2 years, and 1017 (33.4%) were female. Using the CDS definition of METS, 53.2%, 17.2%, 19.8%, and 9.8% of the were more likely to be female and less likely to be current smokers, and those with METS only were younger (Tables 3  and 4 ). As shown in Table 5 , hypertension was the most prevalent metabolic component of METS (CDS), detected in 99.1% of the nondiabetic patients, followed by dyslipidemia (89.9%) and obesity (88.2%), whereas elevated fasting glucose was relatively uncommon (33.1%). . In sensitivity analyses, we observed similar results using the propensity score method (Table 8) . Similar results were observed in the secondary outcomes of composite events and ischemic stroke in both criteria.
Discussion
In this post hoc analysis of the CHANCE study, patients with DM only or concurrent METS and DM had higher recurrent stroke risk than those with neither condition; however, METS only was not associated with stroke recurrence in patients with minor stroke or TIA. There was no difference in the effect of antiplatelet treatment in reducing these events in patients with or without METS or DM.
As we hypothesized, DM only and concurrent METS and DM were significant risk factors of recurrent stroke in patients with minor stroke or TIA in present study. Different from what we expected, METS showed only a trend of increased risk of recurrent stroke and did not reach statistical significance. Even with medical intervention, minor stroke and TIA still led to a high risk of recurrence that could raise the disability rate.
14,15 METS was frequently found in patients with minor Model 2: adjusted for age, sex, history of ischemic stroke, transient ischemic attack, myocardial infarction, angina, congestive heart failure, known atrial fibrillation or flutter, valvular heart disease, smoking status, index event and National Institutes of Health Stroke Scale on admission, and time to randomization. Patients with METS only did not have significantly higher risk of any recurrent stroke than those with neither condition. This finding might be associated with the fact that the definition of METS in our study did not include patients with DM. A previous study showed that METS likely played a crucial role in the development of recurrent ischemic stroke in patients with ischemic stroke or TIA. 10 The definition of METS in this study included DM; however, results of substudies of the SPARCL (Secondary Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels) trial and the SPS3 (Secondary Prevention of Small Subcortical Strokes) study demonstrated that patients with METS only were not at an increased risk of recurrent stroke. 9, 17 Unlike previous studies, the definition of METS in these 2 studies did not include DM, similar to our present study. Consequently, the definition of METS including DM or not might be a factor that influenced the relationship between METS and risk of stroke recurrence.
Several organizations formulated different criteria for METS diagnosis, but all showed 4 main categories of metabolic abnormalities: atherogenic dyslipidemia, increased blood pressure, abnormal glucose regulation, and obesity. 2, 3 Among these factors, abnormal glucose regulation was an established risk factors of recurrent stroke in patients with stroke or TIA. 24 The physiology underlying the elevated risk of recurrent ischemic stroke in diabetic METS may be that it was a recognized risk factor of intracranial atherosclerosis. 25, 26 Previous studies also reported that diabetic METS was associated with recurrent ischemic stroke in patients with large-vessel infarction or lacunar stroke, 10,17 which we
were not able to examine in our study. Patients enrolled in the CHANCE trial primarily were minor stroke patients with stroke subtypes of large-artery atherosclerosis and smallvessel occlusion. 18, 20 Therefore, patients with concurrent METS and DM had higher risk of recurrent stroke than those with nondiabetic METS (METS only) and neither in our study.
In this post hoc analysis, we applied BMI rather than WC for definition of abdominal fat based on a previous study that showed WC and BMI can both be used in the prediction of abdominal visceral obesity for Chinese adults, 1 and the BMI cutoff for abdominal obesity was ≥25. [27] [28] [29] Even so, this still might be a bit inaccurate for the diagnosis of METS (IDF). Nevertheless, it is unlikely that using BMI as a proxy would alter the results because similar patients were diagnosed with METS regardless of whether BMI or WC was used. 30 Large epidemiologic studies have shown a high correlation between BMI and WC. 31 Furthermore, the association between obesity and insulin resistance was similar regardless of whether WC or BMI was used for obesity diagnosis. 32 Using METS with the IDF definition in a sensitivity analysis in our study, the results also demonstrated similar results. Our study has some limitations. First, data on 2-hour plasma glucose, which is an item for assessment of METS (CDS), were not available in the CHANCE trial; therefore, we may have missed some patients who could be diagnosed as having METS. Second, only Chinese patients were enrolled in our study; further evaluation of METS in other races might be required. Third, the characteristics of minor stroke and TIA patients enrolled in this study were different from those of a typical minor stroke or TIA sample from populationbased cohorts. This study enrolled only minor stroke patients with noncardiogenic embolism and high-risk TIA patients (ABCD 2 scores ≥4), which may have resulted in high events rates. Furthermore, large-scale population-based cohorts assessing the association of METS and recurrent stroke are needed to confirm this finding. Finally, duration of DM was not recorded in the CHANCE trial. The duration of DM might be associated with the prognosis of patients with stroke.
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Conclusions
The results from our study showed that patients with DM only or concurrent METS and DM were associated with an elevated risk of stroke among patients with minor ischemic stroke and TIA. Nondiabetic METS (METS only) was not observed to be associated with stroke recurrence in patients with minor stroke or TIA.
